Trends and Finance: Page 3

Ibex, PathPresenter ink partnership

By LabPulse.com staff writers

Ibex Medical Analytics (Ibex) and PathPresenter announced a partnership to enable wider use of AI-enabled digital pathology for their joint customers.

March 6, 2024

Ginkgo Bioworks acquires 3 companies

By LabPulse.com staff writers

Ginkgo Bioworks has acquired three startups: gene-editing diagnostics developer Proof Diagnostics, artificial intelligence (AI)-driven drug discovery company Reverie Labs, and AI platform developer Patch Biosciences.

February 29, 2024

Bruker enters agreement to acquire ELITechGroup

By LabPulse.com staff writers

Life sciences and diagnostics firm Bruker has entered into a definitive share purchase agreement with Paris-based private equity firm PAI Partners to acquire molecular diagnostics firm ELITechGroup, excluding its ELITech clinical chemistry business.

February 28, 2024

Alamar Biosciences raises $100M in series C financing round

By LabPulse.com staff writers

Precision proteomics company Alamar Biosciences has raised $100 million in an oversubscribed series C financing round, with a second close of an additional $28 million anticipated within the next 30 days.

February 27, 2024

German regulatory agency opens review of Thermo Fisher, Olink deal

By LabPulse.com staff writers

Germany’s antitrust regulatory agency, the Bundeskartellamt, has moved into a phase II review of Thermo Fisher’s acquisition of Swedish proteomics firm Olink.

February 22, 2024

Doctor indicted for $20.7M in Medicare fraud

By LabPulse.com staff writers

A federal grand jury in New Jersey indicted Dr. Alexander Baldonado for allegedly engaging in a scheme involving the submission of over $20.7 million in fraudulent claims to Medicare.

February 23, 2024

International consortium aims to develop precision approach for CVD

By Matt Limb

An international collaboration has begun to develop personalized treatments for patients with cardiovascular disease, combining genetic analysis and better integration of health data.

February 21, 2024

Intellia Therapeutics, ReCode Therapeutics to collaborate on genomic medicines for CF

By LabPulse.com staff writers

Gene-editing firm Intellia Therapeutics and biotech company ReCode Therapeutics have entered into a strategic collaboration aimed at developing genomic medicines for the treatment of cystic fibrosis (CF).

February 16, 2024

Freenome raises $254M in funding to advance cancer test pipeline

By LabPulse.com staff writers

Biotech firm Freenome has raised $254 million in new funding from new and existing investors to accelerate its pipeline of early detection cancer tests for its multiomics platform.

February 15, 2024

Invitae files for chapter 11 bankruptcy protection

By LabPulse.com staff writers

Following rumors of imminent bankruptcy, plummeting stock prices, and subsequent trading suspension and delisting on the New York Stock Exchange, Invitae has filed for chapter 11 bankruptcy protection.

February 14, 2024

Roche confirms product development team layoffs

By LabPulse.com staff writers

Roche has confirmed that it plans to lay off several hundred employees from its product development team but has not given specific details.

February 13, 2024

Invitae delisted on NYSE, trading suspended

By LabPulse.com staff writers

Amid a flurry of speculation about the firm’s debt and restructuring plans, Invitae’s stock fell to a precipitous low, prompting the NYSE to suspend trading of the stock and announce that it has begun the process of delisting the company.

February 7, 2024

Previous Page

Page 3 of 132

Next Page